-->

Tag: nivolumab and relatlimab-rmbw

Home / nivolumab and relatlimab-rmbw

Categories

First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma

April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a ...
nivolumab-and-relatlimab-rmbw

Scan the code